20.27
+0.04(+0.20%)
Currency In USD
| Previous Close | 20.23 |
| Open | 20.19 |
| Day High | 20.75 |
| Day Low | 19.92 |
| 52-Week High | 26.58 |
| 52-Week Low | 19 |
| Volume | 659,481 |
| Average Volume | 1.35M |
| Market Cap | 2.48B |
| PE | 12.28 |
| EPS | 1.65 |
| Moving Average 50 Days | 21.88 |
| Moving Average 200 Days | 22.46 |
| Change | 0.04 |
If you invested $1000 in Catalyst Pharmaceuticals, Inc. (CPRX) 10 years ago, it would be worth $4,980.34 as of August 18, 2025 at a share price of $20.27. Whereas If you bought $1000 worth of Catalyst Pharmaceuticals, Inc. (CPRX) shares 5 years ago, it would be worth $5,568.68 as of August 18, 2025 at a share price of $20.27.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)
GlobeNewswire Inc.
Aug 06, 2025 12:03 PM GMT
VGCC antibody testing in conjunction with neurologic consultation can diagnose LEMSAmifampridine may be considered as a supportive care treatmentGuideline inclusion may raise clinical awareness of cancer-associated LEMS to support broader VGCC diagno
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors
GlobeNewswire Inc.
Aug 04, 2025 12:03 PM GMT
CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors. Dr. Curran is a distinguished pharmaceuti
Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
GlobeNewswire Inc.
Jul 22, 2025 12:03 PM GMT
The Company will Host a Conference Call and Webcast on Thursday, August 7, 2025, at 8:30 AM ETCORAL GABLES, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharm